Please use this identifier to cite or link to this item: http://hdl.handle.net/10419/226168
Authors: 
Wu, Xiaoping
Khazin, Bassam Peter
Year of Publication: 
2020
Series/Report no.: 
WTO Staff Working Paper ERSD-2020-12
Abstract: 
COVID-19, caused by SARS-Cov-2, was declared to be a pandemic by the World Health Organization on 11 March 2020. Since then, the issue of the relationship between patent protection and the development of and access to medical treatments and technologies - a longstanding and enduringly important public policy issue - has become central to the debate on the linkages between IP, innovation, access, and public health between stakeholders with divergent interests. This working paper provides an overview of the patent landscape of medical treatments and technologies related to COVID-19, and of the patent status of two investigational medical treatments: remdesivir and lopinavir/ritonavir. It then presents various patent-related actions taken by legislators, policymakers, industry sectors, and civil society organizations in WTO Members since the outbreak. Furthermore, it elaborates on patent-related policy options provided by the TRIPS Agreement, and WTO Members' national implementation and utilization of these options in their response to the COVID-19 pandemic.
Subjects: 
COVID-19 pandemic
patent
open innovation
patentable subject matter
repurposed medicines
exceptions and limitations
licences
government use
transition periods
LDCs
WTO
TRIPS
JEL: 
K11
K15
K30
O30
O31
O34
I18
Document Type: 
Working Paper

Files in This Item:
File
Size





Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.